A phase 1 clinical trial evaluating SCB-1019 compared head-to-head with GSK's AS01E-adjuvanted RSV vaccine (AREXVY) or saline placebo
Latest Information Update: 30 Oct 2024
At a glance
- Drugs SCB-1019 (Primary) ; Respiratory syncytial virus vaccine adjuvanted
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- 30 Oct 2024 New trial record
- 28 Oct 2024 According to Clover media release, as of now 70 patients has been enrolled in this clinical trial.
- 28 Oct 2024 According to Clover media release, company announced positive additional immunogenicity and safety data in older adult & elderly subjects from its Phase 1trial evaluating SCB-1019 compared head-to-head with GSK AS01E-adjuvanted RSV vaccine (AREXVY).